BrainStorm's Workforce Reduction Paves Way for ALS Cell Therapy Market Push

BrainStorm Cell Therapeutics is laying off 30% of its staff as it reevaluates its trial design for its ALS drug, NurOwn, after withdrawing its Biologics License Application (BLA). The company aims to realign its resources for a new clinical trial following a refusal-to-file letter from the FDA and a 17-1 vote by an advisory committee stating that the drug did not demonstrate substantial evidence of effectiveness in a previous study.